Study endpoints
The primary efficacy endpoint was defined as VT recurrence, which
included any ICD appropriate therapy (antitachycardia pacing or shock)
or a documented sustained VT not detected by the ICD. The secondary
efficacy endpoint was defined as all-cause death. The safety outcomes
were defined as 30-day mortality and procedure-related complications.